Ajit Smith-Iyer is the Executive Director of Upstream Process and Platform development at Sutro BioPharma since Nov 2024. He has been in the biotechnology industry for 25yrs and has worked on multiple modalities.
He has a Ph.D in chemical engineering from University of Pennsylvania in non viral gene therapy and started his career at cell genesys, working on CMC aspects of AAV gene therapies and autologous cell therapy. He moved on to Medimmune Vaccines as upstream head for development of cell culture process for manufacturing live attenuated flu vaccine ( FLU MIST). He then moved on to Bayer, where he held multiple different roles in both the clinical and commercial CMC , process engineering and technology and was a key leader in the BLA and commercial launch and support of two new products Kovaltry and Jivi.